PMC3600330_01
Monitoring of dynamic changes of hVOR with the vHIT in intratympanic gentamicin treatment. (a) Before therapy, (b)-(e) 1-4 weeks after therapy. Grey: hVOR: eye acceleration, black: head acceleration. Time-dependent reduction of hVOR gain and appearance of overt and covert refixation saccades.
CRIM.OTOLARYNGOLOGY2013-168391.001.jpg
PMC3600330_01_CRIM.OTOLARYNGOLOGY2013-168391.001.jpg
fig1
At week 2, the hVOR gain was deficient at 0.36 and decreased further to 0.25 and 0.21 at weeks 3 and 4 with a clear appearance of catch-up overt saccades (Figure 1).
ACS cVEMP at 500 Hz (100 dB nHL) before (A) and after intratympanic gentamicin treatment from week 1 (B) to week 2 (C), week 3 (D), and week 4 (E).
CRIM.OTOLARYNGOLOGY2013-168391.002.jpg
PMC3600330_01_CRIM.OTOLARYNGOLOGY2013-168391.002.jpg
fig2
ACS cVEMP, reflecting saccular function, showed normal latencies but a slightly abnormal amplitude asymmetry ratio (AR) of 40% (normal <33%). ACS cVEMP-AR was further reduced from week 1 until week 4 after therapy (Figures 2 and 3).
BCV oVEMP at 500 Hz (100 dB nHL) before (A) and after intratympanic gentamicin treatment from week 1 (B) to week 2 (C), week 3 (D), and week 4 (E).
CRIM.OTOLARYNGOLOGY2013-168391.003.jpg
PMC3600330_01_CRIM.OTOLARYNGOLOGY2013-168391.003.jpg
fig3
ACS cVEMP, reflecting saccular function, showed normal latencies but a slightly abnormal amplitude asymmetry ratio (AR) of 40% (normal <33%). ACS cVEMP-AR was further reduced from week 1 until week 4 after therapy (Figures 2 and 3).
Pure tone audiogram before (open triangle) and 4 weeks after intratympanic gentamicin treatment (open circle) in right-sided Meniere's disease, unaffected left side (asterix).
CRIM.OTOLARYNGOLOGY2013-168391.004.jpg
PMC3600330_01_CRIM.OTOLARYNGOLOGY2013-168391.004.jpg
fig4
BCV oVEMP latencies and AR were normal (<30%) before IGT administration, but AR was successively reduced from week 1 to 4 (Figure 4).